Author:
Sas S,Chan T,Sami A,El-Gayed A,Xiang J
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference62 articles.
1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.
2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340–1349.
3. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA . High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363–3367.
4. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16–20.
5. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ . Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432–436.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献